According to the National Cardiovascular Health Intelligence Network (NCVIN, 2016), co-ordinated by Public Health England, the estimated prevalence gap for people aged 64+ with atrial fibrillation not yet diagnosed is 420,498. Left undetected and untreated, this presents a risk of over 12,600 AF-related strokes per year in England.
Early detection and monitoring can pave the way for better treatment for people with atrial fibrillation; avoidance of the illness, disability and premature death associated with AF-relates stroke and; major healthcare savings. Conservatively an AF-related stroke costs the NHS £12,228 (NICE CG 180) in the first year.
The AliveCor® Kardia Mobile ECG is a mobile heart monitor that allows individuals to detect, monitor and manage heart arrhythmias with automatic analysis. The device can capture electrocardiogram (ECG) recordings of the heart anytime, anywhere, and instantly analyse and interpret heart recordings.
Joining the NHS Innovation Accelerator in July 2015, it is currently being used in over 33 NHS organisations including GP practices and acute trusts across all 15 Academic Health Science Networks, enabling the recording of 1.3million ECGs across the UK. This includes a trial within Care City NHS Test Bed in north-east London, where the device is being used within community pharmacies to screen people over 65 years old across their population of over one million.
The AHSNs will continue to actively support the use of mobile ECG devices during 2017/18, such as the Kardia device, through the national mobile ECG devices fund with the aim of closing the prevalence gap and ensuring more people with AF get appropriately treated to avoid AF-related strokes.